Condition

Metastatic Castration-Resistant Prostate Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 38 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials38
Recruiting11
Common interventions25
Lead sponsors shown15
Advertisement

Clinical trials

38 shown
Clinical Evaluation of SRT-017 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate CancerNCT07798778 · 2026-07-30
RECRUITING
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate CancerNCT07287150 · 2026-03-11
RECRUITING
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)NCT06842498 · 2026-02-22
RECRUITING
A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate CancerNCT07339267 · 2026-01-20
RECRUITING
A Phase I Trial of A-CAR032 in Participants With mCRPCNCT07344311 · 2026-01-13
RECRUITING
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerNCT07005154 · 2025-08-19
RECRUITING
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617NCT06972628 · 2025-05-23
RECRUITING
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerNCT06879041 · 2025-03-10
RECRUITING
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) StudyNCT06531499 · 2024-11-11
RECRUITING
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.NCT06629779 · 2024-10-22
RECRUITING
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate CancerNCT04986423 · 2021-09-08
RECRUITING
REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult ParticipantsNCT07850921 · 2027-06-28
NOT_YET_RECRUITING
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate CancerNCT06318273 · 2024-03-08
ACTIVE_NOT_RECRUITING
A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)NCT06136598 · 2024-01-30
COMPLETED
A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)NCT06104449 · 2023-11-14
COMPLETED
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate CancerNCT05005728 · 2021-10-22
COMPLETED
CATCH-R: A Rollover Study to Provide Continued Access to RucaparibNCT04676334 · 2021-03-22
COMPLETED
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentNCT04647526 · 2021-02-25
ACTIVE_NOT_RECRUITING
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate CancerNCT04666129 · 2021-02-18
COMPLETED
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate CancerNCT04408924 · 2021-01-20
COMPLETED
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate CancerNCT04419402 · 2020-08-17
ACTIVE_NOT_RECRUITING
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEnNCT04256993 · 2020-02-15
COMPLETED
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate CancerNCT03414034 · 2018-08-14
COMPLETED
Study to Evaluate CCS1477 in Advanced TumoursNCT03568656 · 2018-07-23
COMPLETED
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT03437941 · 2018-02-20
TERMINATED
A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate CancerNCT03137758 · 2017-07-24
TERMINATED
A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate CancerNCT02711956 · 2016-12-01
COMPLETED
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)NCT02861573 · 2016-11-17
ACTIVE_NOT_RECRUITING
A Study of ZEN003694 in Patients With Metastatic Castration-Resistant Prostate CancerNCT02705469 · 2016-05-01
COMPLETED
A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyNCT02405858 · 2015-04-10
COMPLETED
Sequencing Abiraterone and Enzalutamide in mCRPCNCT02125357 · 2014-09-01
COMPLETED
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate CancerNCT02123758 · 2014-07-09
ACTIVE_NOT_RECRUITING
A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate CancerNCT02116582 · 2014-05-23
COMPLETED
Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) PatientsNCT02091531 · 2014-03-01
COMPLETED
A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate CancerNCT01663415 · 2012-08-01
WITHDRAWN
A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer PatientsNCT01650194 · 2012-07-09
COMPLETED
Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)NCT05650476
AVAILABLE
Provide Expanded Access to MDV3100 and Monitor Its Safety in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based ChemotherapyNCT01606982
APPROVED_FOR_MARKETING

Trial status mix

COMPLETED16
RECRUITING11
ACTIVE_NOT_RECRUITING5
TERMINATED2
APPROVED_FOR_MARKETING1
AVAILABLE1
NOT_YET_RECRUITING1
WITHDRAWN1

Phase mix

PHASE218
PHASE116
PHASE33
PHASE42
EARLY_PHASE11
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.